Company: IRadimed Corporation
Ticker: Nasdaq: IRMD
Sector: Healthcare
Investor Contact: Joe Dorame

IRadimed Corporation News

News

IRADIMED Names John F. Glenn Chief Financial Officer

WINTER SPRINGS, Fla., May 26, 2022 -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John (Jack) Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022. Mr. Glenn will assume responsibility for all areas of accounting and...

IRADIMED CORPORATION Announces First Quarter 2022 Financial Results

Reports first quarter 2022 revenue of $12.3 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.22Announces second quarter 2022 financial guidanceIncreases full-year 2022 financial guidance WINTER SPRINGS, Fla., April 29, 2022 -- IRADIMED CORPORATION...

IRADIMED CORPORATION Announces Executive Transition

WINTER SPRINGS, Fla., April 28, 2022 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), announced today announced that Chris Scott, Chief Financial and Operating Officer, has resigned from the Company effective May 27, 2022. Mr. Scott started at the Company in...

IRADIMED Announces Special $1.00 Per Share Cash Dividend

WINTER SPRINGS, Fla., Feb. 07, 2022 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), announced that its Board of Directors approved a special cash dividend of $1.00 per share on the Company's outstanding common stock. This special cash dividend is payable on...

IRADIMED CORPORATION Announces Fourth Quarter 2021 Financial Results

Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33Announces full-year and first quarter 2022 financial guidance WINTER SPRINGS, Fla., Feb. 04, 2022 -- iRadimed Corporation (the "Company") (NASDAQ: IRMD), a...

IRADIMED CORPORATION Announces Third Quarter 2021 Financial Results

Reports third quarter 2021 revenue of $10.9 million, GAAP diluted EPS of $0.20 and non-GAAP diluted EPS of $0.23Increases full-year 2021 financial guidance WINTER SPRINGS, Fla., Oct. 29, 2021 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), a leader in the...

IRADIMED CORPORATION Announces Second Quarter 2021 Financial Results

Reports second quarter 2021 revenue of $9.8 million, GAAP diluted EPS of $0.12 and non-GAAP diluted EPS of $0.14Issues Q3 and full year 2021 financial guidance WINTER SPRINGS, Fla., July 30, 2021 -- IRADIMED CORPORATION (the "Company") (NASDAQ: IRMD), a leader in the...

Skip to content